Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
BiomeSense logo — Developing novel tools to enable the routine, low-cost analy...

BiomeSense

Developing novel tools to enable the routine, low-cost analysis of human microbiome data.

Founded 2018 United States Chicago, United States 15 employees Venture round Total: $12.61M Analytics, Biotechnology +3

General Information

Company Name BiomeSense
Founded Year 2018
Location United States Chicago, United States
Employees 15
Industries Analytics, Biotechnology, Health Care +2
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with BiomeSense. To contact BiomeSense, visit biomesense.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BiomeSense compare?

A PDF of BiomeSense and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BiomeSense soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BiomeSense

BiomeSense is a groundbreaking startup in the biotech and health care industries, aiming to revolutionize human microbiome research. The company's slogan, "Developing novel tools to enable the routine, low-cost analysis of human microbiome data." succinctly captures its mission. Founded in 2018 and headquartered in the United States, BiomeSense has attracted significant attention with its recent $6.18M Venture Round investment in December 2023. The company's innovative approach involves creating tools to track, analyze, and store daily microbiome profiles of clinical trial participants. This pioneering method provides a wealth of data at a fraction of the current cost, offering investigators unprecedented insight into the intricate relationship between the microbiome and clinical interventions. BiomeSense's disruptive technology has the potential to significantly advance human microbiome research, with implications for various aspects of healthcare and beyond. In the rapidly evolving landscape of biotechnology and health care analytics, BiomeSense's approach holds promise for transforming the way we understand and utilize microbiome data. As the company continues to attract significant investments, it is poised to make a substantial impact on the field and potentially shape the future of human microbiome research.

Business keywords: microbiome research, data analysis tools, clinical trials, biome profiling, microbiome influence, clinical interventions

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $6.18M -
19 Dec 2023
Seed Round $3.00M 7
Bluestein Ventures SOSV Nameless Ventures
Bluestein Ventures, SOSV +5
05 Feb 2023
Seed Round Undisclosed 1
IrishAngels
IrishAngels
04 Feb 2022
Convertible Note $500.00K -
01 Sep 2021
Convertible Note Undisclosed 1
SOSV
SOSV
02 Jun 2021
Grant $255.66K 1
National Science Foundation
National Science Foundation
06 Jan 2021
Seed Round Undisclosed 1
IrishAngels
IrishAngels
05 Jan 2021
Convertible Note Undisclosed 2
SOSV indiebio
SOSV, indiebio
23 Nov 2020
Seed Round $2.42M 3
SOSV Seerave Foundation
SOSV, Seerave Foundation +1
02 Oct 2019
Seed Round Undisclosed 2
SOSV indiebio
SOSV, indiebio
20 Feb 2019

View All 11 Funding Rounds

Latest News

View All
Bluestein Ventures raises $45M for third food tech fund — Techcrunch
Bluestein Ventures raises $45M for third food tech fund
Techcrunch Feb 20, 2024

BiomeSense Alternatives & Competitors

View All Alternatives
BiomeSense vs
PharmaBiome AG
PharmaBiome AG Switzerland

Pioneering the development of microbiome-based therapies using proprietary tools for their design an...

Convertible Note
11 employees
Biotechnology, Health Care
BiomeSense vs
REM Analytics
REM Analytics Switzerland

REM Analytics measures the microtype of people for the microbiome industry to improve product impact...

4 employees
Analytics, Biotechnology
BiomeSense vs
IDEXX BioAnalytics
IDEXX BioAnalytics United States

Customized Testing Solutions, Meaningful Data And Global Expertise In Research Testing Services.

108 employees
Biotechnology, Health Care
View all alternatives

FAQ About BiomeSense

Developing novel tools to enable the routine, low-cost analysis of human microbiome data.
BiomeSense was founded in 2018.
BiomeSense is headquartered in Chicago, United States.
BiomeSense operates in Analytics, Biotechnology, Health Care, Life Sciences and Clean Energy. Its work centres on microbiome research, data analysis tools, clinical trials and biome profiling.
BiomeSense has approximately 15 employees.
BiomeSense has completed 11 funding rounds, raising a total of $12.61M. The latest funding stage is Venture round.
Top alternatives and competitors to BiomeSense include PharmaBiome AG, REM Analytics, IDEXX BioAnalytics, Microbiotica , Medlab Clinical Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BiomeSense and PharmaBiome AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BiomeSense, https://bouncewatch.com/company/biomesense, updated 2 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes